Aglocell Delivers Tier-1 U.S. Carrier 1 Terabyte of Additional Daily Network Capacity in Live Trial and Dramatically Improved Customer Experience in Separate Deployment

AI-powered software unlocks the equivalent of potential more than a billion dollars in

capacity across a major carrier's national footprint without adding any hardware

WARRENVILLE, Ill., Sept. 28, 2026 /PRNewswire/ -- Aglocell, Inc. (Aglocell), a developer of AI-powered wireless network optimization software, announced results from live network trials with a U.S. Tier-1 wireless carrier that delivered dramatic capacity and performance improvements using software only. Across two distinctly different markets, a 60-plus site network in a major metropolitan area and a customer-experience-focused deployment in a rural market, Aglocell's SpectraMax software demonstrated that carriers can unlock significant new value from their existing infrastructure without the cost and complexity of expensive network capacity buildouts.

"We found a terabyte of additional capacity in this carrier's network, clearly demonstrating that by leveraging our SpectraMax technology, wireless networks can dramatically unlock capacity at a fraction of the cost of legacy physical rollouts," said Bruce Peterson, Founder and Managing Director of Aglocell. "That's the equivalent of adding roughly a third of an entirely new layer of spectrum capacity, which would normally cost the carrier approximately $43,000 per cell site in new hardware, tower climbs and deployment. When you multiply that across a national footprint of tens-of-thousands of sites, you're looking at more than a billion dollars in value that can be realized through software instead of spectrum, radios, steel and concrete."

The results come at a critical time for the wireless industry. According to Dell'Oro Group, Radio Access Network (RAN) capital expenditure is forecast to remain flat or decline over the next five years, forcing carriers to find more cost efficient ways to improve network capacity, quality and experience. Traditional approaches to expanding network capacity, which include purchasing spectrum licenses, purchasing and deploying new RAN hardware, and dispatching tower crews are expensive, time-consuming and increasingly difficult to justify under ongoing revenue pressures.

Metro Area Case Study: Turning Existing Spectrum Into Millions in Savings

Aglocell deployed SpectraMax across 60-plus cell sites in a major U.S. city and achieved a 4.1% network-wide capacity increase during the peak busy hour, the equivalent of approximately one terabyte of additional data throughput. In carrier terms, that gain represents one-third of a full new frequency layer, a physical buildout that would typically cost the operator $43,000 per cell site, or nearly $2.6 million across those 60-plus sites. Instead, Aglocell delivered approximately $2.6 million in equivalent capacity value at a fraction of the cost, representing a potential10x return on investment. The carrier has signaled plans to expand the deployment to a significantly larger market cluster.

Rural Market Case Study: Improving the Everyday Customer Experience

In a separate trial in a more rural area, Aglocell addressed a different customer challenge: the quality of everyday wireless service. Using SpectraMax with newly enhanced optimization features, Aglocell improved network quality, elevating the carrier's RootMetrics® US Overall RootScore®, which is a composite score made of numerous network quality measurements.

During this trial, SpectraMax showed dramatic improvement in several areas including call handling, reliability and responsiveness. Call handling evaluates how reliably a call can be initiated and held without dropping. Reliability measures the ability to access the network without blocks and drops. Responsiveness measures how quickly and smoothly the network handles common user tasks like browsing or launching applications. The improvement in these areas helped boost the overall network ranking into a first-place tie in the test market. The carrier has previously correlated similar network performance gains with measurable improvements in customer satisfaction scores and growth in subscriber revenue.

"Aglocell's ability to show concrete capacity gains and real customer experience improvements across two very different markets allows them to differentiate themselves from traditional and competitive offerings," said Patrick Lopez, CEO of {Core Analysis}. "As carriers face flat or declining capital budgets, software-driven approaches like this will become a critical factor in driving subscriber growth and increasing revenue."

Aglocell's SpectraMax platform is designed to operate across multiple vendor environments, supporting leading automation platforms including the Ericsson Intelligent Automation Platform (EIAP) and Snowflake, with integration planned for Nokia MantaRay and Samsung's SMO solution. This open, vendor-agnostic architecture allows carriers with multi-vendor networks to deploy a single optimization engine rather than managing separate tools for each equipment provider, avoiding vendor lock-in.

Additional SpectraMax Benefits:

- Real-Time AI Optimization: SpectraMax leverages advanced AI to automatically and continuously find and fix performance bottlenecks across 4G and 5G networks.

- Increased Network Capacity Requiring No New Hardware: Live 60-plus site trial produced one terabyte of additional peak-hour capacity by intelligently redistributing traffic across the carrier's existing towers and spectrum, the equivalent of adding costly new infrastructure.

- Millions in Avoided Capex Spending: Software-driven RAN capacity scaling eliminates network exhaustion, lowering capital costs during a period of tightening wireless budgets.

SpectraMax is commercially available and operational today. For more information, visit aglocell.com.

About Aglocell

Aglocell, Inc. develops AI-driven solutions that automate and optimize wireless networks globally. Founded in 2019, the company's advanced algorithms enhance spectral efficiency, streamline operational workflows and unlock new performance and financial value for mobile network operators. Aglocell's technology builds on capabilities acquired from BandwidthX in December 2023. For more information, visit aglocell.com.

SOURCE Aglocell

Share this article

If You Purchased Ready-Mix Concrete Directly From Lafarge, Argos, Coastal, Thomas, Evans Or Elite In The Greater Savannah Area From January 1, 2010 Through July 31, 2016, You May Be Entitled to Share In The Distribution of Settlement Proceeds.

News provided by

CohenMalad, LLP, Heins Mills & Olson, P.L.C., and Preti Flaherty Beliveau & Pachios LLP

Sep 28, 2026, 08:00 ET

CHARLESTON, S.C., Sept. 28, 2026 /PRNewswire/ -- CohenMalad, LLP, Heins Mills & Olson, P.L.C., and Preti Flaherty Beliveau & Pachios LLP announce that the United States District Court for the District of South Carolina has granted final approval to settlements with Lafarge North America, Inc. ("Lafarge"), Thomas Concrete, Inc. and Thomas Concrete of South Carolina, Inc. (together, "Thomas") and Evans Concrete, LLC ("Evans") (collectively, the "Settlements"), and has approved a plan of distribution of the amounts paid pursuant to those Settlements.

The Settlements are part of a class action lawsuit against Lafarge, Thomas, Evans, Argos USA LLC and Argos Ready Mix LLC (together, "Argos"), Coastal Concrete Southeast II, LLC ("Coastal") and Elite Concrete, LLC ("Elite"), which claims that these companies participated in an unlawful conspiracy to raise, fix, maintain, or stabilize the price of Ready-Mix Concrete from January 1, 2010 through July 31, 2016. The lawsuit is entitled Pro Slab, Inc., et al. v. Argos USA LLC, et al., Case No. 2:17-cv-03185-BHH ("Lawsuit"). Lafarge, Thomas, Evans, Argos, Coastal and Elite are collectively the "Defendants."

Who is eligible to submit a Claim? You are a "Settlement Class Member" and eligible to file a Claim Form to share in distributions from the Settlements if you purchased Ready-Mix Concrete directly from one or more of several "Subject Plants" operated by any of the Defendants at any time from January 1, 2010 through and including July 31, 2016 (the "Class Period"). A list of the Subject Plants can be found at www.SavannahConcreteCase.com.

If you previously requested exclusion from one or more of the Settlements, you are not eligible to file a Claim Form and receive distributions from that Settlement.

How do I submit a Claim? All Settlement Class Members who wish to receive any of the Lafarge, Thomas or Evans Settlement funds recovered in the Lawsuit MUST submit a Claim Form by:

- Visiting the Settlement Website at www.SavannahConcreteCase.com to complete a Claim Form and file your claim online by November 16, 2026; or

- Requesting a Claim Form from the Settlement Administrator at 1-888-999-5317 or [email protected], completing and signing the Claim Form, and mailing it to the Settlement Administrator so that it is postmarked by November 16, 2026.

Please visit the Settlement Website at www.SavannahConcreteCase.com for more information about filing a Claim Form.

Are all of my purchases from the Defendants eligible for Claims? Settlement Class Member distributions will be based on the amount of their "Qualifying Purchases" of Ready-Mix Concrete, which are those direct purchases of Ready-Mix Concrete from one of the Subject Plants during the Class Period for which a completed and signed Claim Form has been submitted. "Qualifying Purchases" do not include materials or products other than Ready-Mix Concrete, such as separately charged admixtures, material additives or building materials, or separately charged service fees. However, Qualifying Purchases do include environmental fees, fuel surcharges and minimum load charges.

How are Qualifying Purchases determined? For many Settlement Class Members, the amount of their Qualifying Purchases can be determined from records provided by the Defendants. To find out if Qualifying Purchase information is available for you from the Defendants' records, visit the Settlement Website at www.SavannahConcreteCase.com to begin the claims process, or contact the Settlement Administrator at 1-888-999-5317 or [email protected].

Qualifying Purchase information from Defendants' records is incomplete for some Settlement Class Members. If you believe the information available from Defendants' records does not include some or all of your Qualifying Purchases, you will have the opportunity to submit a Claim Form with supporting documentation identifying additional Qualifying Purchases.

How much will I receive from the Settlements? The amount a Settlement Class Member will receive from the Settlements will be determined by dividing the amount of their Qualifying Purchases by the total amount of other Settlement Class Members' Qualifying Purchases to calculate a pro rata percentage, which will then be applied to the funds available for distribution from the Settlements.

Because the pro rata amount a Settlement Class Member will receive depends on the amounts of other Settlement Class Members' Qualifying Purchases, it is not possible to determine the amount of any distributions until after all Claim Forms are submitted and processed.

Please Act Promptly. Your Eligibility to Share in Settlement Distributions is Limited By the Deadlines Stated Above.

Please do not contact the Court regarding this Notice.

1-888-999-5317, [email protected]

SOURCE CohenMalad, LLP, Heins Mills & Olson, P.L.C., and Preti Flaherty Beliveau & Pachios LLP

Share this article

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

- JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1

- Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuum

- Approval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile

NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.

JUVMO Is a New Kind of Treatment for Parkinson's Disease

"The approval of JUVMO marks the first dopaminergic breakthrough for Parkinson's disease in decades," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "People living with Parkinson's and the clinicians who care for them have long faced difficult tradeoffs between motor control, treatment burden and tolerability. Clinicians now have a new treatment option that targets dopamine pathways differently and reduces the difficult tradeoffs associated with D2/D3 selective dopamine agonists."

Needed Innovation in the Parkinson's Disease Treatment Landscape

For people living with Parkinson's disease, maintaining consistent control of motor symptoms becomes increasingly challenging as the disease progresses. Oral levodopa remains the foundation of treatment and is often effective at controlling symptoms, but many patients require higher and more frequent doses over time. These adjustments can help restore symptom control yet may also contribute to treatment-related complications such as dyskinesia. About 70% of people living with Parkinson's disease have their oral levodopa dose increased within the first year of therapy.2

These challenges highlight the need for new treatment approaches that can help address the evolving needs of people living with Parkinson's disease. After 85 weeks on JUVMO, 93% of clinical trial participants had not increased their oral levodopa dose and 94% of participants with early Parkinson's disease had not started oral levodopa.3

Dopamine agonists have long been used to help manage symptoms and reduce reliance on oral levodopa escalation. However, currently available dopamine agonists primarily target D2/D3 receptors and their use may be limited by tolerability concerns. JUVMO introduces a different approach, selectively targeting D1/D5 receptors to provide health care providers and patients with a new option for managing motor symptoms across the Parkinson's disease continuum.

Why the Approval of JUVMO Matters for People across the Spectrum of the Disease

"Parkinson's disease treatment has long required health care providers to balance the need for dependable motor symptom control with considerations around treatment tolerability," said Hubert Fernandez, M.D., professor of neurology at the Cleveland Clinic Lerner College of Medicine and global principal TEMPO trial investigator. "Now we have a novel therapy that selectively targets D1/D5 receptors, which addresses a longstanding need for innovation and provides health care providers with greater flexibility to tailor treatment to individual patient needs."

Perspective from the Parkinson's Community

"For people with Parkinson's and their families, progress means having treatment options that deliver meaningful benefit in everyday life," said Brian Fiske, PhD, chief scientist of The Michael J. Fox Foundation for Parkinson's Research. "Each therapy approval is an important milestone in building a diverse treatment pipeline needed to meet the full range of unmet needs across the Parkinson's community."

AbbVie expects to make JUVMO available to patients in the U.S. in October 2026.

FDA Approval Was Supported by Phase 3 TEMPO Clinical Trial Data

Phase 3 data from the TEMPO clinical trial program demonstrated the efficacy and safety of JUVMO in people with early Parkinson's disease who were not taking oral levodopa (TEMPO-1 and 2) and as an adjunct to oral levodopa in people with Parkinson's disease experiencing motor fluctuations (TEMPO-3).1

- In TEMPO-1 at week 26, JUVMO significantly improved activities of daily living scores versus placebo, as measured by MDS-UPDRS Part II, which includes everyday tasks like dressing, eating and personal hygiene (placebo: +0.9; 5 mg: -1.6; 15 mg: -1.7; p 0.0001 each dose versus placebo).1

- Compared to baseline, JUVMO improved activities of daily living scores by 22-23% whereas the placebo group worsened by 12%.

- Additionally, JUVMO significantly improved activities of daily living and motor skills, as measured by MDS-UPDRS Part II + III combined scores, versus placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2; p 0.0001 each dose versus placebo) at week 26.4

- JUVMO also significantly improved MDS-UPDRS Part II scores versus placebo in TEMPO-2 at week 26 (placebo: 0.0; 5-15 mg: -1.5; p =0.0007).1

- JUVMO also significantly improved MDS-UPDRS Part II + III combined scores versus placebo in TEMPO-2 at week 26 (placebo: -1.2; 5-15mg: -10.3; p 0.0001).5

- In TEMPO-3 at week 26, JUVMO 5-15 mg + oral levodopa significantly increased total daily "on" time without troublesome dyskinesia versus placebo + oral levodopa (1.7 hours versus 0.6 hours, p 0.0001).1

- Total daily "off" time decreased by 1.9 hours with JUVMO + oral levodopa, compared to a decrease of 0.9 hours with placebo + oral levodopa (p =0.0006).

- Sustained efficacy was observed out to 85 weeks for those who continued in the open-label extension period (TEMPO-4).3

- Of those on JUVMO + oral levodopa for 85 weeks, 93% did not increase their oral levodopa dose (96/103). Of those on JUVMO without levodopa, 94% did not initiate levodopa (257/273).3

- The majority of treatment-emergent adverse events (TEAEs) were non-serious and mild or moderate in severity.1

- The most common TEAEs for JUVMO without oral levodopa, reported in ≥5% of patients, were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth and anxiety.

- For JUVMO + oral levodopa, the most common TEAEs, reported in ≥5% of patients, were nausea, dyskinesia, dizziness, headache, hallucinations and orthostatic hypotension.

About Parkinson's Disease

More than 11 million people worldwide are living with Parkinson's disease,6 a progressive and chronic neurological disorder characterized by tremor, muscle rigidity, slowness of movement and difficulty with balance.7

The motor symptoms of Parkinson's disease begin when approximately 60-80% of the dopamine-producing cells in the brain are lost and symptoms continue to worsen slowly over the course of time.8

As Parkinson's disease progresses, patients may experience complications, including motor and non-motor fluctuations and dyskinesia. Patients report switching from an "on" state (when symptoms are generally well controlled) to an "off" state, during which symptoms such as tremor and stiffness may reappear and patients may have more difficulty moving.9 Patients with later-stage Parkinson's disease may also experience dyskinesia (involuntary movements), which can significantly hinder daily activities.9

USE

JUVMO is a prescription medicine used for the treatment of Parkinson's disease in adults. It is not known if JUVMO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Tell your healthcare provider about all your medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, as JUVMO (tavapadon) and certain other medicines may affect each other and how they work.

JUVMO may cause serious side effects. Talk to your healthcare provider before starting JUVMO and while on JUVMO if you have had or have any of the following:

- Low blood pressure. This is a common side effect and may be serious. JUVMO can lower your blood pressure and make you feel dizzy, especially when you stand up (orthostatic hypotension). Do not get up too fast from sitting or after lying down. You may be more likely to feel dizzy after starting JUVMO or when your dose is increased.

- Unusual urges. Some people taking medicines for Parkinson's disease, including JUVMO, have had unusual urges. This may include gambling, compulsive eating, compulsive shopping, and increased sex drive.

- Seeing, hearing, or feeling things that are not real (hallucinations). This is a common side effect and may be serious. Tell your healthcare provider if you have a mental health problem such as hallucinations.

- Uncontrolled sudden movements (dyskinesia). This is a common side effect and may be serious. If you have new dyskinesia or your dyskinesia gets worse, tell your healthcare provider. This may be a sign that your dose of JUVMO or other Parkinson's medicines may need to be adjusted.

The most common side effects of JUVMO include nausea, headache, change in taste, feeling tired (fatigue), vomiting, dry mouth, and anxiety.

These are not all the possible side effects of JUVMO. For more information, ask your healthcare provider or pharmacist.

JUVMO tablet for oral use is available as 5 mg, 10 mg, and 15 mg tablets, as well as 0.25 mg and 1 mg tablets contained in a Titration Pack.

Please see the full Prescribing Information, including Patient Information. Talk to your healthcare provider if you have questions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question is shifting from whether RAS can be drugged to how long those responses can be made to last. Active Companies from around the markets with current developments this week include: Oncolytics Biotech® Inc. (Nasdaq: ONCY), Revolution Medicines, Inc. (Nasdaq: RVMD), Amgen Inc. (Nasdaq: AMGN), Eli Lilly and Company (NYSE: LLY), and Verastem Oncology (Nasdaq: VSTM).

Other forecasters size the category differently but point in the same direction. Roots Analysis projects the global KRAS market will grow from approximately $557 million in 2025 to approximately $3.98 billion by 2035, a CAGR of about 21%, and expects intravenously administered therapies to grow at a faster rate than the oral drugs that dominate the category today.

The scale of the opportunity comes down to how common these mutations are. KRAS mutations account for approximately 85% of RAS-associated cancers in humans, including about 90% of pancreatic cancers, according to Eli Lilly and Company. In colorectal cancer, KRAS mutations appear in approximately 40% of all cases, according to Amgen, yet the G12C subtype that the first approved inhibitors were built to target is present in only about 3% to 5% of colorectal cancers. That gap is why the pipeline has moved toward multi-selective and mutation-specific agents aimed at G12D, G12V and other variants that drive pancreatic and colorectal disease.

The clinical bar moved sharply in April 2026, when a Phase 3 trial of an oral RAS(ON) multi-selective inhibitor in previously treated metastatic pancreatic cancer reported a median overall survival of 13.2 months versus 6.7 months for chemotherapy, according to the sponsor's SEC filing. Results like that have changed the conversation. With RAS inhibition now showing it can extend survival in one of the hardest cancers to treat, attention is turning to what limits it: tumors that adapt, and responses that fade as resistance emerges.

That is where combination strategies come in. Developers are pairing RAS blockade with EGFR antibodies, chemotherapy, immunotherapy and other agents in an effort to deepen responses and push resistance further out. Among the approaches being tested is whether an agent that engages the immune system through a different mechanism can work alongside RAS inhibition rather than against it.

Oncolytics Biotech® Inc. (Nasdaq: ONCY) Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

- Pelareorep activity was maintained in the presence of RAS inhibition, with no evidence of antagonism between the two therapies in a RAS-driven colorectal cancer model

- Findings support further evaluation of optimized pelareorep dosing with RAS inhibitors and the hypothesis that it could deepen or prolong responses to RAS-targeted therapy

- FDA written feedback in August 2026 aligned on a potential pivotal Part B expansion of the ongoing REO 033 colorectal cancer study

- Pelareorep holds FDA Fast Track designation in colorectal, anal and pancreatic cancer

Oncolytics Biotech (Nasdaq: ONCY), a clinical-stage immunotherapy company developing pelareorep, announced positive preclinical results on September 10, 2026, from a study evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial treatment period, when pelareorep was administered every other day, pelareorep, the pan-RAS inhibitor and the combination each reduced tumor growth compared to the control. The greatest tumor reductions were observed in the RAS inhibitor and combination groups, showing that pelareorep activity was maintained alongside RAS inhibition without evidence of antagonism.

The Company was direct about the limits of the result. Following the transition to less frequent weekly pelareorep dosing, the incremental activity associated with pelareorep became less evident. Oncolytics said that, taken together, the findings support further evaluation of optimized pelareorep dosing with RAS inhibitors, and the hypothesis that sustained pelareorep activity could potentially deepen or prolong responses to RAS-targeted therapy and thereby delay the emergence of resistance. The Company also noted the findings are consistent with previously published independent research showing that RAS inhibitors do not interfere with the mechanism through which pelareorep selectively infects tumor cells.

"These results provide an encouraging first look at combining pelareorep with one of the most important emerging classes of targeted cancer therapies," said Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics. "We observed pelareorep activity during the initial intensive dosing period as well as biologic compatibility between pelareorep and RAS inhibition, supporting the continued evaluation of pelareorep/RAS inhibitor combination therapy. Because acquired resistance remains a major limitation of RAS-targeted therapies, we believe these findings provide a compelling rationale to investigate whether sustained pelareorep activity can deepen and prolong responses to RAS inhibition and potentially delay the emergence of resistance. Similarly, pelareorep, because of its unique mechanism of action, may offer a treatment option for patients who become resistant to RAS inhibitors."

Oncolytics plans to expand its preclinical evaluation of pelareorep with RAS inhibitors across additional dosing schedules and RAS-driven tumor models, designed to further characterize pelareorep's contribution to the combination, including its potential impact on the depth and durability of tumor response and the development of resistance.

Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action: it selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses. It has been administered to over 1,200 patients, and the Company is advancing it in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers.

The preclinical work sits alongside a colorectal program already moving toward a registrational decision. On August 18, 2026, Oncolytics announced it had received written feedback from the FDA on the design of a potential pivotal Part B expansion of REO 033, its ongoing randomized study of pelareorep with FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab alone in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. The Company said the feedback represents important alignment on a pathway in which objective response rate could support potential accelerated approval and progression-free survival could support full approval. The FDA also suggested an End-of-Phase meeting to reach final agreement on key elements of the registration program.

"We are thrilled with the response provided by the FDA and believe this feedback could support a highly efficient path to potentially transition REO 033 from its ongoing randomized Part A directly into a pivotal Part B," said Jared Kelly, Chief Executive Officer of Oncolytics. "Importantly, the feedback provides alignment around the potential use of response rate to support an accelerated approval pathway and progression-free survival to support full approval."

The ongoing Part A enrolls 60 patients, and the Company intends to decide whether to launch the pivotal expansion once initial clinical data from Part A are available. Elsewhere in the portfolio, pelareorep received Fast Track designation in July 2026 in combination with a checkpoint inhibitor for second-line and later squamous cell anal cancer, following April 2026 FDA alignment on a pivotal study design in that indication. Oncolytics has also secured a new U.S. patent covering key aspects of pelareorep's commercial manufacturing process, which the Company expects to provide protection into 2044.

There are several risks associated with the Company's plans. The RAS combination findings are preclinical results from a single colorectal cancer model, and preclinical results may not be predictive of results in clinical studies; the Company itself reported that pelareorep's incremental contribution became less evident under weekly dosing. No clinical data combining pelareorep with a RAS inhibitor have been reported. Pelareorep is investigational and has not been approved by the FDA or any other regulator for any indication. FDA written feedback and Fast Track designation do not guarantee approval, the End-of-Phase meeting has not yet been held, and the decision to launch REO 033 Part B depends on Part A data that are not yet available. As a clinical-stage company, Oncolytics will require additional capital to advance its programs and is pursuing strategic partnerships that may not materialize. Readers should review the Company's filings on EDGAR and SEDAR+ and the forward-looking statements in its releases.

Read this and more news for Biotech Sector at: http://Equity-Insider.com

In other industry developments and happenings in the market this week include:

Revolution Medicines, Inc.

Duck Creek Launches Agentic FNOL to Transform Claims Intake with Intelligent, Real-Time Automation

New solution uses AI Agents orchestrated to capture, validate and route claims across channels, helping insurers improve first-contact data quality, accelerate claims handling, and enhance the policyholder experience

BOSTON, Sept. 28, 2026 /PRNewswire/ -- Duck Creek, the intelligent core of insurance, today announced Duck Creek Agentic First Notice of Loss (FNOL), an AI-powered solution that transforms claims intake into an intelligent, real-time experience, is now available for early access customers.

Built on the Duck Creek Agentic AI Platform, Agentic FNOL uses orchestrated and extensible AI agents to capture, validate, enrich, and route claims across digital, voice-to-text, and mobile channels. The solution helps insurers improve data quality at first contact, reduce claims cycle times, lower loss adjustment expense, and deliver a more responsive experience for policyholders at a critical moment.

"First notice of loss sets the trajectory for the entire claims experience," said Jose Lazares, Chief Product Officer at Duck Creek. "With Agentic FNOL, insurers can replace fragmented, manual intake processes with an intelligent experience that captures the right information, verifies coverage, identifies potential issues early, and moves each claim to the right next step. This gives claims teams greater capacity to focus on the decisions and customer interactions where their expertise has the greatest impact."

Celent's most recent annual survey on generative AI usage in insurance found that 22% of participating insurers plan to have an agentic AI solution in place by the end of 2026, and Celent expects claims and underwriting to be among the areas that lead adoption.

Through the digital customer experience, Agentic FNOL enables claimants to report a loss in their own words rather than navigate a rigid form. The solution listens to natural-language inputs, determines the right follow-up questions, and delivers a structured, enriched, adjuster-ready claim file in seconds.

From the first description of a loss, Agentic FNOL verifies coverage, assesses injury and legal severity, and identifies anomaly signals across claim characteristics without manual data entry. It cross-references reported circumstances, submitted images, policy data, and the broader claim record to surface inconsistencies that may warrant closer review. Each AI-driven determination is clearly logged, with exceptions flagged for human review, so adjusters can begin informed conversations with claimants and focus on support and resolution rather than administrative intake.

"For years, adjusters have begun work on claims that are incomplete, unverified, and missing critical context, creating manual follow-up that adds cost and delays a claimant's path to resolution," said Ella Jurotte, Senior Director, Product Management at Duck Creek. "With Agentic FNOL, enrichment begins the moment a loss is reported. By the time an adjuster opens the file, coverage has been verified, anomaly signals have been assessed, and the claim has been routed to the right next step. It gives adjusters more time to focus on informed decisions and meaningful claimant interactions, while delivering a faster, more consistent experience from the first notice of loss."

Agentic FNOL brings insurance-specific intelligence and governance directly into the claims intake process. By combining Duck Creek's core system data, insurance domain models, and AI orchestration, the solution enables agents to work within carrier-defined workflows, rules, and controls. Every AI-driven action is designed to be traceable, explainable, and auditable.

Developed in collaboration with Google Cloud and powered by Gemini models, Agentic FNOL supports critical intake capabilities, including:

- Policy and coverage verification to help ensure claims are accurately associated with the appropriate policy and coverage information

- Conversational claims intake across digital, voice-to-text, and mobile channels

- Data capture and validation that improves submission quality and completeness at first contact

- Intelligent triage and routing to direct claims efficiently based on carrier-defined workflows

- Early fraud and anomaly detection to help identify potential concerns during intake

- Real-time integration with claims data and workflows to support faster, more informed handling

Agentic FNOL is designed to seamlessly work with Duck Creek Claims and can support third-party core system environments, allowing insurers to introduce agentic capabilities while preserving their existing technology investments. The solution combines autonomous automation with human-in-the-loop controls, helping carriers scale claims operations without sacrificing oversight, compliance, or the human judgment required for complex claims.

Agentic FNOL is part of Duck Creek's growing portfolio of agentic applications, which also include Agentic Underwriting and Agentic Product Configurator. Together, these solutions extend intelligent, governed automation across the insurance lifecycle, helping carriers move beyond task-level AI to orchestrated end-to-end workflows.

About Duck Creek Technologies

Duck Creek is the intelligent core that leading insurers choose to build on. Purpose-built for property and casualty (P&C) and general insurance, Duck Creek unifies the full insurance lifecycle on a single platform with one data foundation. As an agentic platform, it connects intelligence across underwriting, policy, billing, claims, reinsurance, and payment workflows where decisions are made and compliance is non-negotiable. Duck Creek enables carriers to launch products faster, adapt quickly to change, and grow with precision and confidence. Solutions are available individually or as a full suite via Duck Creek OnDemand. Visit www.duckcreek.com and follow Duck Creek on LinkedIn and X.

Media Contact

Tara Lefave Stred / Marianne Dempsey

[email protected] 

SOURCE Duck Creek

Share this article

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE: LAZ) announced today that Pranjal Gambhir joined the firm as Head of Medical Technology, based in New York.

In this role, Pranjal will lead coverage of Medical Technology companies, advising clients on strategy and corporate development transactions across the sector.

"Pranjal has broad and deep experience across the Medical Technology sector, and his arrival deepens the coverage we can offer clients," said David Gluckman, Global Head of Healthcare at Lazard. "His background across multiple sub-sectors gives our Healthcare Group added strategic depth as we continue to grow our practice."

Pranjal joins Lazard from Citi, where he was most recently Managing Director covering Medical Technology companies across multiple sub-sectors. He spent 20 years at Citi across various roles in New York and New Delhi.

"The Medical Technology sector continues to evolve rapidly, creating both opportunity and complexity for clients," said Pranjal Gambhir. "Lazard's independent perspective and global platform are exactly what leadership teams, boards and investors need, and I look forward to helping them navigate what's ahead. "

Pranjal earned his MBA from the Indian School of Business and Bachelor of Commerce from Delhi University.

Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.

Media Relations         

Jessica Francisco

+1 212-632-6571

[email protected]

Shannon Houston

+1 212-632-6880                   

[email protected]

Investor Relations

William Murdock

+1 212-632-1564

[email protected] 

SOURCE Lazard

Share this article

Bybit and Franklin Templeton Form Strategic Collaboration to Expand Access to Tokenized Investing

The wider collaboration launches with a new off-exchange collateral program that unlocks trading liquidity for institutional clients, alongside initiatives to bring tokenized wealth and yield-generation strategies to wallet-based investors

DUBAI, UAE, Sept. 28, 2026 /PRNewswire/ -- Bybit, the New Financial Platform trusted by more than 80 million users worldwide, today announced a strategic collaboration with Franklin Templeton, a global investment leader with $1.7 trillion in assets under management* and a pioneer in digital asset innovation.

The collaboration's first initiative allows eligible clients to use tokenized money market fund shares as off-exchange collateral when trading on Bybit. The shares are issued through the Benji Technology Platform, Franklin Templeton's proprietary blockchain-integrated recordkeeping and transfer agency infrastructure.

Eligible investors can now pledge Benji-issued fund shares through ByCustody, an institutional-grade custody platform, to access USDT or USDC trading credit lines on Bybit while the underlying tokenized assets remain held off-exchange in custody. The value is mirrored within Bybit's trading environment, allowing clients to continue earning yield on holdings while supporting their trading activity.

"As institutional adoption of digital assets accelerates, investors increasingly expect the same flexibility, capital efficiency, and risk management standards they are accustomed to in traditional markets," said Yoyee Wang, Global Head of RWA and TradFi at Bybit. "By expanding the range of high-quality collateral available through our off-exchange infrastructure, we are helping clients deploy capital more effectively while maintaining exposure to trusted, regulated investment products."

The program extends Bybit's growing suite of institutional infrastructure, giving eligible clients another way to access trading liquidity against regulated, yield-bearing collateral without moving those assets onto the exchange, reducing counterparty exposure and improving capital efficiency and treasury management.

The collaboration also extends to wallet-based investors, with a tokenized wealth product on the Bybit exchange and Mantle chain that provides access to Franklin Templeton investment strategies. Bybit and Mantle will share further details separately.

Franklin Templeton and Bybit will also release digital content programs and education initiatives designed to help wallet-based retail investors explore traditional investment strategies and better understand concepts like goals-based investing and diversification.

"Tokenization continues to reshape finance, and we're excited to partner with Bybit to increase access to actively managed retail investment solutions that meet the evolving needs of the wallet ecosystem," said Sandy Kaul, Head of Digital Assets and Innovation at Franklin Templeton. "For institutions, extending connectivity of the Benji Technology Platform to Bybit offers a trusted venue to put regulated, yield-bearing assets to work in digital markets, and is a great example of how blockchain-integrated solutions can drive innovation and efficiency across markets."

These initiatives mark the beginning of a broader collaboration between Franklin Templeton and Bybit aimed at closing the distance between regulated investment management and on-chain markets. For institutions, that means the collateral, custody, and capital efficiency standards familiar from traditional finance, applied inside a digital asset trading environment. For wallet-based investors, it means access to professionally managed strategies, and the education to use them, in the venues where they hold their assets.

#Bybit / #NewFinancialPlatform

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That's why we're building the first intelligent platform that connects anyone, anywhere to the world's finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: [email protected]

For updates, please follow: Bybit's Communities and Social Media

Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

SOURCE Bybit

Share this article

CHICAGO, Sept. 28, 2026 /PRNewswire/ -- Trading Technologies International, Inc. (TT), a global capital markets technology provider, today announced the promotion of Maxime Jeanniard du Dot to EVP, Margin Analytics. In that role, he leads the TT Margin business, created following TT's acquisition of OpenGamma in December.

Jeanniard du Dot served as Chief Operating Officer of OpenGamma for 10 years prior to the acquisition.

Alun Green, EVP, Managing Director, Futures and Options, said: "OpenGamma is the industry-leading solution for margin analytics, helping our clients save billions of dollars in capital every year. Maxime is the ideal choice to assume responsibility for TT Margin to continue OpenGamma's leading role in providing margin analytics services to the world's largest hedge funds, asset managers, commodity trading firms and banks. He understands the challenges our customers face along with the efficiencies and insights our products can provide across all asset classes and trade flows. He will be instrumental as we introduce cross-asset margin optimization to meet the growing demand for cross-asset trading from our clients."

Prior to OpenGamma, Jeanniard du Dot was Trading Platform Owner for HSBC's cleared over-the-counter (OTC) derivatives in London. He previously was a Market Specialist at Calypso Technology and served as an Analyst at Accenture in the greater Paris metropolitan region.

About Trading Technologies

Trading Technologies (www.tradingtechnologies.com), owned by Thoma Bravo and 7RIDGE, is a global capital markets platform services company providing market-leading technology for the end-to-end trading operations of Tier 1 banks, brokerages, money managers, hedge funds, proprietary traders, Commodity Trading Advisors (CTAs), commercial hedgers and risk managers. With its roots in listed derivatives, the Software-as-a-Service (SaaS) company delivers "multi-X" solutions across asset classes, functions, workflows and geographies. The TT platform ecosystem features trade execution across futures, options, fixed income, foreign exchange (FX) and cryptocurrencies, augmented by solutions for data and margin analytics, trade surveillance, clearing and post-trade allocation.

SOURCE Trading Technologies

Share this article

Parking leader expands Florida presence with new self-park garage along the Bayshore corridor

TAMPA, Fla., Sept. 28, 2026 /PRNewswire/ -- Universal Parking, a leading innovator in the parking industry, today announces its latest parking management contract for Bayshore Gardens, one of South Tampa's most desirable office environments, located off Bayshore Boulevard.

Steps from Hillsborough Bay, Bayshore Gardens combines premier office space with walkability, waterfront proximity, and a variety of surrounding retail and dining options. The self-park garage, with an entrance on S. Ysabella Avenue between Barcelona Wine Bar and Altura Bayshore, offers covered parking, accessible parking spaces and touchless parking options designed to provide a convenient arrival and departure experience.

"We're excited to continue our partnership with Asana Partners to enhance the experience at Bayshore Gardens," said Justin Kinsey, CPP, Vice President of Operations – Central Florida at Universal Parking. "As South Tampa continues to grow, our goal is to deliver a seamless parking experience, making it easier for tenants and visitors to access the property and surrounding areas."

With the addition of Bayshore Gardens, Universal Parking continues to expand its footprint across high-profile mixed-use and hospitality destinations throughout the Southeast, remaining focused on delivering innovative parking solutions tailored to complex, high-traffic urban environments.

To learn more about Universal Parking and the projects it supports, visit universalparking.com

About Universal Parking

Universal Parking provides tailored parking management services on behalf of property owners and asset managers. With a leadership team boasting over 175 years of combined experience, Universal Parking specializes in operating complex and diverse parking facilities while leveraging technology and customer-focused strategies to enhance the parking experience.

Media Contact

Clare Meyers

[email protected]

On behalf of Universal Parking

SOURCE Universal Parking

Share this article

SJE strengthens engineered control solutions for water and wastewater markets

DETROIT LAKES, Minn., Sept. 28, 2026 /PRNewswire/ -- SJE, Inc., the global industry leader in control systems, today announced the acquisition of Wilson Controls, LLC, a provider of automation and control solutions for water, wastewater, and environmental applications. The acquisition expands SJE's PLC and SCADA systems integration, instrumentation, and UL-listed control panel capabilities while strengthening the company's presence across New England.

Located in Lee, New Hampshire, Wilson Controls was founded in 2012. The company engineers, programs, integrates, and supports PLC and SCADA systems, instrumentation, and control panels. Its UL 508A and UL 698A panel capabilities serve municipal and industrial customers throughout New England and beyond.

"Wilson Controls is a strong strategic fit for SJE," said Bjorn Haldorsen, CEO of SJE. "Their engineering expertise, regional customer relationships, and complete automation solutions complement our Engineered Control Solutions business. Together, we can offer customers broader capabilities backed by responsive service."

"Wilson Controls has always focused on understanding each customer's process and delivering a reliable system that meets the project's requirements," said Scott E. Drapeau, P.E., owner of Wilson Controls. "Joining SJE gives our team additional resources while preserving the technical focus and customer commitment that define our work."

"Wilson Controls adds experienced automation professionals and an important New England presence," said Andy Wilson, President of SJE's Engineered Control Solutions Division. "Their strengths in PLC and SCADA integration, instrumentation, and UL-listed panel fabrication align closely with our work for water, wastewater, and industrial customers."

"SJE remains focused on delivering reliable control and automation solutions for critical infrastructure," said Haldorsen. "Wilson Controls helps us support more customers from engineering and panel fabrication through programming, startup, training, and long-term service."

About SJE Inc.

SJE® was founded in 1975. Over 50 years later, SJE has evolved into a global industry leader in control systems, operating throughout the United States and Canada, as well as in international markets. SJE, a privately held company, is comprised of over thirteen well-respected brands known for their innovation and quality. SJE has locations throughout the United States, Mexico, and Asia. SJE offers a wide variety of control products for residential, commercial, municipal, water, wastewater, and industrial markets, representing the most reliable integration of engineering and manufacturing capabilities in the industry. To learn more, visit www.sjeinc.com.

About Wilson Controls

Located in Lee, New Hampshire, Wilson Controls, LLC provides automation and control solutions for water, wastewater, environmental, and industrial applications. Founded in 2012, Wilson Controls has extensive experience in PLC and SCADA programming and integration, instrumentation, control and monitoring systems, UL 508A and UL 698A control panel manufacturing, engineering, testing, maintenance, startup, training, and operations documentation. Wilson Controls serves customers throughout New England and supports select projects beyond the region. To learn more, visit www.wilson-controls.com.

SOURCE SJE Inc

Share this article